Wedbush Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics (NASDAQ:STOK) had its price objective hoisted by investment analysts at Wedbush from $38.00 to $40.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective would suggest a potential upside of 35.32% from the company’s current price.

A number of other research analysts have also recently issued reports on the stock. The Goldman Sachs Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 target price for the company. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 11th. Canaccord Genuity Group reduced their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday. Weiss Ratings downgraded Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Chardan Capital reissued a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.00.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $29.56 on Tuesday. Stoke Therapeutics has a one year low of $12.71 and a one year high of $40.22. The firm has a market capitalization of $1.84 billion, a P/E ratio of -10.52 and a beta of 1.20. The company’s fifty day moving average is $30.39 and its two-hundred day moving average is $32.00.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. On average, sell-side analysts forecast that Stoke Therapeutics will post -3.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the sale, the insider owned 34,826 shares in the company, valued at approximately $1,064,979.08. This represents a 4.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total value of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares of the company’s stock, valued at $541,675.70. The trade was a 7.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.60% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics during the 4th quarter worth about $26,000. KBC Group NV purchased a new stake in shares of Stoke Therapeutics during the first quarter worth about $36,000. Harbour Investments Inc. raised its position in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the period.

Key Headlines Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed its “Buy” rating and assigned a $35 price target, implying approximately 18% upside from the referenced $29.56 level. This provides a positive analyst catalyst for STOK. Benzinga analyst rating report
• Positive Sentiment: Second-quarter revenue was about $9.3 million, well above the $4.89 million consensus estimate. The result suggests stronger-than-anticipated revenue generation and may help offset concerns about the company’s ongoing cash burn. Zacks second-quarter earnings report
• Neutral Sentiment: Management provided business updates on zorevunersen, Stoke’s lead investigational RNA medicine and potential disease-modifying treatment for Dravet syndrome, including progress in its global development program. Investors are likely focused on clinical execution and future regulatory milestones. Stoke Therapeutics second-quarter business update
• Neutral Sentiment: Brokerages collectively rate STOK “Moderate Buy,” indicating generally favorable but not uniformly bullish expectations. Brokerage recommendation report
• Negative Sentiment: Stoke reported a quarterly loss of $0.93 per share, missing estimates of roughly $0.80–$0.82 and widening from a $0.40 loss a year earlier. Its negative net margin and return on equity underscore continued substantial operating losses. Stoke Therapeutics earnings report

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.